Carbohydrate antigen 19-9 as a prognostic biomarker in pancreatic neuroendocrine tumors
Luo G, Jin K, Cheng H, Liu C, Guo M, Lu Y, Yang C, Xu J, Wang W, Gao H, Zhang S, Long J, Xu J, Ni Q, Chen J, Yu X. Carbohydrate antigen 19-9 as a prognostic biomarker in pancreatic neuroendocrine tumors. Oncology Letters 2017, 14: 6795-6800. PMID: 29163700, PMCID: PMC5688789, DOI: 10.3892/ol.2017.7071.Peer-Reviewed Original ResearchPancreatic neuroendocrine tumorsCA19-9 levelsCA19-9Carbohydrate antigen 19Overall survivalPrognostic factorsAntigen 19Neuroendocrine tumorsPrognostic biomarkerMajority of PNETsTumor node metastasis (TNM) stage IIIROC curveBaseline CA19-9 levelsSerum CA19-9 levelsMetastasis stage IIIPrimary end pointAdverse prognostic factorPatients' overall survivalExpression levelsConsecutive patientsPresent studySingle institutionAbnormal elevationStage IIINormal rangeNeutrophil-lymphocyte ratio predicts survival in pancreatic neuroendocrine tumors
Luo G, Liu C, Cheng H, Jin K, Guo M, Lu Y, Long J, Xu J, Ni Q, Chen J, Yu X. Neutrophil-lymphocyte ratio predicts survival in pancreatic neuroendocrine tumors. Oncology Letters 2017, 13: 2454-2458. PMID: 28454419, PMCID: PMC5403377, DOI: 10.3892/ol.2017.5716.Peer-Reviewed Original ResearchNeutrophil-lymphocyte ratioPancreatic neuroendocrine tumorsOverall survivalPrognostic factorsPrognostic roleNeuroendocrine tumorsRole of NLRBaseline NLR levelHigh-risk patientsKaplan-Meier methodPoor prognostic factorTNM stage IIIROC curveG2/G3Variety of tumorsNLR levelsNLR valuesConsecutive patientsIndependent predictorsTumor sizeSingle institutionClinical dataStage IIIAggressive characteristicsPatients